Xtant Medical Q3 revenue misses estimates; withdraws guidance
XTNT•Xtant Medical reported Q3 revenue of $24.30 million, below the $25.51 million estimate, and a $0.03-per-share loss, versus an estimated $0.02 loss. It withdrew its 2026 guidance and launched a strategic review.
1. Quarterly results
Q3 revenue fell to $24.30 million, missing the $25.51 million analyst estimate. The company reported a net loss of $3.60 million, or $0.03 per share, compared with estimates of $3.31 million and $0.02 per share. It said the revenue decline mainly reflected the absence of revenue from divested non-core businesses and wound care licensing. Biologics revenue rose 13% year over year and 11% sequentially, helped by HEMOBLAST sales, while gross margin fell due to lost high-margin wound care licensing revenue and sales mix.
2. Guidance and review
Xtant Medical withdrew its previously issued full-year 2026 guidance and will not provide revised guidance. Its board launched a strategic review of operational and financial alternatives, with no set timetable. The company expects cash and credit availability to fund operations for at least the next 12 months.



